Is BIOA-B.ST overvalued or undervalued?

BIOA-B.ST currently has a P/E ratio of 248.24. Relative to the sector average of 36.50, this suggests the stock may be overvalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy BioArctic AB stock?

BioArctic AB trades on STO. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of BIOA-B.ST?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying BIOA-B.ST protect my money against local inflation?

Many investors in Latin America buy international stocks like BIOA-B.ST to protect their purchasing power. Because BIOA-B.ST is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy BIOA-B.ST shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is BIOA-B.ST a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well BIOA-B.ST diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksBIOA-B.ST

BioArctic AB

kr 295.40+kr 5.00+1.72%

STO / SEK

Market cap

kr 26.2B

P/E

248.2

EPS (TTM)

kr 0.13

Dividend yield

0.68%

Beta

-0.69

1Y return

-1.40%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$3M2021

$22M2022

$61M2023

$23M2024

$216M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.04Low
Current ratio3.99
Cash ratio1.61
Net margin10.5%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

BIOA-B.ST248.2
Healthcare sector median36.5
S&P 50022.0

Trades about 580% above its sector, the market expects faster growth.

Ratios

PEG-2.75
Price to book13.00
EPS (TTM)kr 0.13
Payout ratio0%
FCF yield5.16%

Range & risk

kr 257.00kr 364.40

Trading in the middle of its 52-week band

Beta-0.69

Profile

What BioArctic AB actually does

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

CEO

Gunilla Christina Osswald

Employees

150

Headquarters

Stockholm, AB

Founded

2017-10-12

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save BIOA-B.ST and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

BIOA-B.ST has a beta of -0.69, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

BioArctic AB